SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca - Yahoo Finance
2 days ago • Google News
Summit Therapeutics PLC (SMMT)
US$ 24.290.37%
Price Chart
Key Statistics
Market Cap
$ 17.07B
P/E Ratio
0.00
Revenue (TTM)
$ 0
Volume
3.1M
52W High
$ 36.91
52W Low
$ 8.24
Dividend Yield
0.00%
Beta
-1.05
Technicals
50-Day MA
22.7155
200-Day MA
20.8918
52 Week High
36.91
52 Week Low
8.24
About SMMT
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.
Employees
159
Headquarters
Miami, FL
CEO
Mr. Robert W. Duggan
Latest News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg